Edgewise Therapeutics, Inc. EWTX
47.57 USD +1.04 (+2.24%)
At closeNov 12, 2026, 4:41 AM EST
47.25 -0.32 -0.67%
Pre-market · Nov 12, 4:41 AM ET
45.62 Day range 47.85
19.76 52-week range 48.78
- YTD
- +91.66%
- 1 year
- +121.46%
News
prnewswire.com Edgewise Therapeutics to Participate in Upcoming Investor Conferences BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that management will…
benzinga.com Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $51 Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $53 to $51.
benzinga.com Edgewise Therapeutics Says Edgewise Has Submitted STRATUS-HCM Phase 3 Protocol Following End-Of-Phase 2 Meeting – STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM populations under a single master protocol, with peak VO₂ as the primary endpoint…
prnewswire.com Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring – Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two…
benzinga.com Edgewise Therapeutics Q3 Adj. EPS $(0.19) Misses $2.48 Estimate Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $2.48 by 107.66 percent. This is a 51.28 percent increase over losses…
benzinga.com William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating William Blair analyst Alethia Young initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating.